Medizin 3

Publications: Priv.-Doz. Dr. med. J. Rech

Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J: Effects of Conventional Uric Acid-Lowering Therapy on Monosodium Urate Crystal Deposits Arthritis Rheumatol. 2020;72(1): 150-156
Steffen U, Koeleman CA, Sokolova MV, Bang H, Kleyer A, Rech J, Unterweger H, Schicht M, Garreis F, Hahn J, Andes FT, Hartmann F, Hahn M, Mahajan A, Paulsen F, Hoffmann M, Lochnit G, Munoz LE, Wuhrer M, Falck D, Herrmann M, Schett G: IgA subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun. 2020;11(1):
Simon D, Berlin A, Tascilar K, Bayat S, Engelke K, Rech J, Figuereido C, Hueber A, Schett G, Kleyer A: THE PHYSIOLOGICAL FINGER JOINT ARCHITECTURE - AGE-RELATED INCREASE OF EROSIONS AND OSTEOPHYTES IN THE JOINTS OF HEALTHY INDIVIDUALS Ann Rheum Dis. 2019;78(): 602-603
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N: ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL Rheumatology (Oxford). 2019;58():
Liphardt AM, Liehr S, Manger E, Bieniek L, Kleyer A, Simon D, Tascilar K, Sticherling M, Rech J, Schett G, Hueber A: HAND FUNCTION IS IMPAIRED IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND PSORIASIS COMPARED TO HEALTHY CONTROLS Ann Rheum Dis. 2019;78(): 2126-2126
Berlin A, Simon D, Tascilar K, Figueiredo C, Bayat S, Finzel S, Klaus E, Rech J, Hueber AJ, Kleyer A, Schett G: The ageing joint-standard age- and sex-related values of bone erosions and osteophytes in the hand joints of healthy individuals. Osteoarthritis Cartilage. 2019;27(7): 1043-1047
Simon D, Tascilar K, Unbehend S, Bayat S, Meinderink T, Berlin A, Rech J, Hueber A, Schett G, Kleyer A: IMPACT OF PRIMARY HAND OSTEOARTHRITIS ON MICROSTRUCTURE AND BIOMECHANICS IN FINGER JOINTS Ann Rheum Dis. 2019;78(): 1868-1868
Kleyer A, Simon D, Bui CD, Hueber A, Bang H, Ramming A, Rech J, Kroenke G, Schett G: MICRO-STRUCTURAL CHANGES ASSOCIATED WITH ANTI-CITRULLINATED VIMENTIN AUTOIMMUNITY IN RA-AT-RISK INDIVIDUALS PRECIPITATE THE ONSET OF RHEUMATOID ARTHRITIS Ann Rheum Dis. 2019;78(): 133-133
Boeltz S, Hagen M, Knopf J, Mahajan A, Schick M, Zhao Y, Erfurt-Berge C, Rech J, Munoz LE, Herrmann M: Towards a pro-resolving concept in systemic lupus erythematosus Semin Immunopathol. 2019;41(6): 681-697
Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J: Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status. J Rheumatol. 2019;46(5): 460-466
Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J, Schett G: Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019;78(9): 1186-1191
Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Rech J, Kleyer A, Schett G, Sticherling M, Hueber AJ: Interleukin 17 Blockade in Psoriasis Patients with Subclinical Joint Inflammation- Prospective Open Study to Influence the Course of the Disease by means of Secukinumab J Dtsch Dermatol Ges. 2019;17(): 127-128
Kampylafka E, Englbrecht M, Tascilar K, Lerchen V, Linz C, Kleyer A, Simon D, Rech J, Schett G, Hueber A: COMPARATIVE CHANGE IN QUALITY OF LIFE MEASURES IN PRECLINICAL AND ESTABLISHED PSORIATIC ARTHRITIS PATIENTSUNDER SECUKINUMAB TREATMENT. DATA DERIVED FROM THE PROSPECTIVE OPEN LABEL PSARTROS STUDY Ann Rheum Dis. 2019;78(): 1845-1845
Hagen M, Tascilar K, Reiser M, Haschka J, Kleyer A, Valor L, Manger B, Schett G, Rech J: Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission Arthritis Rheumatol. 2019;71():
Haschka J, Simon D, Bayat S, Kleyer A, Kampylafka E, Hueber A, Muschitz C, Skalicky S, Hackl M, Resch H, Schett G, Kocijan R, Rech J: Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement Arthritis Rheumatol. 2019;71():
Valor L, Hagen M, Reiser M, Kleyer A, Hartmann F, Manger B, Schett G, Rech J, Tascilar K, Haschka J, Englbrecht M, Hueber A, Figueiredo C, Fogagnolo J, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Retro: FACTORS ASSOCIATED WITH PERSISTENT DRUG-FREE REMISSION IN PATIENTS WITH RHEUMATOID ARTHRITIS Ann Rheum Dis. 2019;78(): 730-730
Schett G, Simon D, Hueber A, Bang H, Rech J, Kroenke G, Kleyer A: Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients Arthritis Rheumatol. 2019;71():
Valor L, Schenker H, Knitza J, Hagen M, Rech J, Schett G: Polyautoimmunity and Major Organ Involvement Prevalence in Sjogren's Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study Arthritis Rheumatol. 2019;71():
de Moel EC, Rech J, Mahler M, Roth J, Vogl T, Schouffoer A, Goekoop RJ, Huizinga TWJ, Allaart CF, Toes REM, Schett G, van der Woude D: Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs Arthritis Res Ther. 2019;21(1):
Valor L, Schenker H, Hagen M, Knitza J, Rech J, Schett G: THE ANTI-RO52 PREVALENCE IN THE SJOGREN'S SYNDROME PICTURE: A SINGLE CENTER CROSS SECTIONAL STUDY Ann Rheum Dis. 2019;78(): 1180-1180
Valor L, Hagen M, Reiser M, Hartmann F, Kleyer A, Manger B, Schett G, Rech J, Tascilar K: Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis Arthritis Rheumatol. 2019;71():
Valor L, Schenker H, Hagen M, Knitza J, Rech J, Schett G: POLYAUTOIMMUNITY AND MAJOR ORGAN INVOLVEMENT PREVALENCE IN SJOGREN'S SYNDROME: THYROID, LIVER, LUNG AND KIDNEY AS TARGETS. A SINGLE CENTER CROSS SECTIONAL STUDY Ann Rheum Dis. 2019;78(): 1744-1745
Hueffmeier UD, Loehr S, Ekici AB, Uebe S, Koehm M, Behrens F, Boehm B, Sticherling M, Schett G, Moessner R, Nimeh A, Assmann G, Rech J, Oji V, Holmdahl R, Burkhardt H, Reis A: Association analyses of functional NCF1 variants in psoriatic arthritis and psoriasis vulgaris Eur J Hum Genet. 2019;27(): 125-125
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N: Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis Rheumatol. 2019;71(8): 1329-1338
Bayat S, Ellmann H, Araujo E, Manger B, Hagen M, Kleyer A, Cavallaro A, Lell M, Schenker H, Simon D, Tascilar K, Baraf HSB, Schett G, Rech J: SIZE MATTERS - EXTENT OF MONOSODIUM URATE DEPOSITS BUT NOT SERUM URATE LEVEL PREDICTS COMPLETE RESOLUTION OF MONOSODIUM URATE CRYSTAL DEPOSITS IN PATIENTS WITH GOUT Ann Rheum Dis. 2019;78(): 1295-1296
de Moel E, Rech J, Mahler M, Roth J, Schouffoer A, Ronday K, Huizinga T, Allaart CF, Toes R, Schett G, van der Woude D: Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA Arthritis Rheumatol. 2019;71():
Simon D, Kleyer A, Bayat S, Tascilar K, Kampylafka E, Meinderink T, Schuster L, Petrov R, Liphardt AM, Rech J, Schett G, Hueber AJ: Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients Arthritis Res Ther. 2019;21():
Sokolova M, Nas K, Luo YB, Simon D, Zhao Y, Rech J, Zaiss M, Schett G: A SET OF INFLAMMATORY MARKERS ALLOWING TO DETECT SYSTEMIC INFLAMMATION IN PSORIATIC SKIN, ENTHESEAL AND JOINT DISEASE IN THE ABSENCE OF CRP AND THEIR LINK TO CLINICAL DISEASE MANIFESTATION Ann Rheum Dis. 2019;78(): 175-176
Schonau V, Roth J, Tascilar K, Rech J, Schmidt D, Kuwert T, Crescentini F, Boiardi L, Casali MI, Versari A, Schett G, Salvarani C, Muratore F: RESOLUTION OF VASCULAR INFLAMMATION IN PATIENTS WITH GIANT CELL ARTERITIS RECEIVING GLUCOCORTICOIDS, METHOTREXATE OR TOCILIZUMAB TREATMENT-DATA FROM THE ITALIAN/GERMAN RIGA STUDY Ann Rheum Dis. 2019;78(): 591-591
Schoenau V, Roth J, Tascilar K, Rech J, Schmidt D, Kuwert T, Crescentini F, Boiardi L, Casali M, Verson A, Pazzola G, Schett G, Salvarani C, Muratore F: Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study Arthritis Rheumatol. 2019;71():
Stephan M, Tascilar K, Hagen M, Haschka J, Reiser M, Hartmann F, Kleyer A, Hueber A, Manger B, Figuereido C, Cobra J, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G, Rech J: PHYSICAL FUNCTION IN RA PATIENTS IN REMISSION UNDERGOING TAPERING AND/OR STOPPING OF DMARDS Ann Rheum Dis. 2019;78(): 321-322
Hannemann N, Cao S, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Uebe S, Ekici A, Rech J, Baeuerle T, Bogdan C, Vera J, Schett G, Bozec A: INHIBITION OF ARGINASE-1 EXPRESSION BY THE TRANSCRIPTION FACTOR FRA-1 IN MACROPHAGES EXACERBATES RHEUMATOID ARTHRITIS INFLAMMATION Ann Rheum Dis. 2019;78(): A27-A27
Valor L, Schenker H, Knitza J, Hagen M, Rech J, Schett G: The anti-Ro52 Prevalence in the Sjogren's Syndrome Picture: A Single Center Cross Sectional Study Arthritis Rheumatol. 2019;71():
Hannemann N, Cao S, Eriksson D, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Rech J, Ramming A, Uebe S, Ekici A, Canete JD, Chen XX, Baeuerle T, Vera J, Bogdan C, Schett G, Bozec A: Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis J Clin Invest. 2019;129(7): 2669-2684
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera RF, Unizony SH, Collinson N: EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL Rheumatology (Oxford). 2019;58():
Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid M, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony S, Collinson N: EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL Rheumatology (Oxford). 2019;58():
Löhr S, Ekici AB, Uebe S, Büttner C, Köhm M, Behrens F, Böhm B, Sticherling M, Schett G, Simon D, Mössner R, Nimeh A, Oji V, Assmann G, Rech J, Holmdahl R, Burkhardt H, Reis A, Hüffmeier U: Analyses of association of psoriatic arthritis and psoriasis vulgaris with functional NCF1 variants. Rheumatology (Oxford). 2019;58(5): 915-917
Simon D, Bayat S, Tascilar K, Kampylafka E, Meinderink T, Schuster L, Liphardt AM, Rech J, Hueber A, Schett G, Kleyer A: EFFECT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON BONE STRUCTURE AND STRENGTH IN PSORIATIC ARTHRITIS PATIENTS Ann Rheum Dis. 2019;78(): 1287-1287
Kampylafka E, Simon D, d'Oliveira I, Linz C, Lerchen V, Englbrecht M, Rech J, Kleyer A, Sticherling M, Schett G, Hueber AJ: Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. Arthritis Res Ther. 2019;21(1):
Araujo EG, Englbrecht M, Hoepken S, Finzel S, Kampylafka E, Kleyer A, Bayat S, Schoenau V, Hueber A, Rech J, Schett G: Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum. 2019;48(4): 632-637
Haeger J, Bang H, Hagen M, Frech M, Traeger P, Sokolova MV, Steffen U, Tascilar K, Sarter K, Schett G, Rech J, Zaiss MM: The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility Study Nutrients. 2019;11(10):
Schoenau V, Roth J, Englbrecht M, Rech J, Schett G: Does an 18f-FDG-PET/CT in Patients with Giant Cell Arteritis in Clinical Remission Make Sense? Arthritis Rheumatol. 2018;70():
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera RF, Unizony SH, Collinson N: Effects of Baseline Prednisone Dose on Remission and Disease Flare in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomized Controlled Trial Arthritis Rheumatol. 2018;70():
Figueiredo CP, Kleyer A, Simon D, Stemmler F, d'Oliveira I, Weissenfels A, Museyko O, Friedberger A, Hueber AJ, Haschka J, Englbrecht M, Pereira RMR, Rech J, Schett G, Engelke K: Methods for segmentation of rheumatoid arthritis bone erosions in high-resolution peripheral quantitative computed tomography (HR-pQCT). Semin Arthritis Rheum. 2018;47(5): 611-618
Mease P, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, Ligozio G, Abrams K, Pricop L: SECUKINUMAB EFFICACY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: META-ANALYSIS OF 4 PHASE 3 TRIALS Acta Derm Venereol. 2018;98(): 15-16
Alten R, Burkhardt H, Feist E, Krüger K, Rech J, Rubbert-Roth A, Voll RE, Elbez Y, Rauch C: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Arthritis Res Ther. 2018;20(1): 1
Jünemann A, Hohberger B, Rech J, Sheriff A, Fu Q, Schlötzer-Schrehardt U, Voll RE, Bartel S, Kalbacher H, Hoebeke J, Rejdak R, Horn F, Wallukat G, Kunze R, Herrmann M: Agonistic Autoantibodies to the β2-Adrenergic Receptor Involved in the Pathogenesis of Open-Angle Glaucoma. Front Immunol. 2018;9():
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ: Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Ann Rheum Dis. 2018;77(6): 840-847
Sighart R, Rech J, Hueber A, Blank N, Löhr S, Reis A, Sticht H, Hüffmeier U: Evidence for genetic overlap between adult onset Still's disease and hereditary periodic fever syndromes. Rheumatol Int. 2018;38(1): 111-120
Kampylafka E, Oliveira I, Linz C, Lerchen V, Englbrecht M, Simon D, Sticherling M, Rech J, Kleyer A, Schett G, Hueber AJ: Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab - Data from a Prospective Open Label Study Arthritis Rheumatol. 2018;70():
Soare A, Weber S, Maul L, Rauber S, Gheorghiu AM, Houssni I, Kleyer A, Luber M, Rech J, Schett G, Distler J, Ramming A: INNATE LYMPHOID CELLS CORRELATE WITH DISEASE ACTIVITY AND BONE REMODELLING IN PSORIATIC ARTHRITIS Ann Rheum Dis. 2018;77(): 116-116
Biermann MHC, Boeltz S, Pieterse E, Knopf J, Rech J, Bilyy R, van der Vlag J, Tincani A, Distler JHW, Kroenke G, Schett GA, Herrmann M, Munoz LE: Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus Front Immunol. 2018;9():
Simon D, Unbehend S, Bayat S, Rech J, Hueber AJ, Schett G, Kleyer A: The Influence of Hand Osteoarthritis on Bone Microstructure and Biomechanical Properties of Radial Bone Arthritis Rheumatol. 2018;70():
Schett G, Finze S, Kraus S, Regensburger A, Kocijan R, Rech J: TOCILIZUMAB ACHIEVES BETTER REPAIR OF FOCAL BONE EROSIONS THAN TUMOUR NECROSIS FACTOR INHIBITION IN RA PATIENTS - DATA FROM THE PROSPECTIVE REBONE STUDY ON EROSION REPAIR Ann Rheum Dis. 2018;77(): 572-572
McInnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, Ding K, Ilsley E, Pricop L: Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study Arthritis Rheumatol. 2018;70():
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N, GiACTA Investigators: ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL Ann Rheum Dis. 2018;77(): 1120-1121
Rech J, Arnulf B, Mellon CDM, Malphettes M, Vignon M, Lavergne D, Kambouchner M, Meignin V, Bergeron A, Brillet P, Nunes H, Jaccard A, Valeyre D, Uzunhan Y: Presentation, Survival and Factors of Survival in Respiratory Tract Amyloidosis: A French Consecutive Case Series of 72 Patients Am J Respir Crit Care Med. 2018;197():
Neumann A, Haschka J, Kleyer A, Schuster L, Englbrecht M, Berlin A, Figueiredo CP, Simon D, Muschitz C, Kocijan R, Resch H, Rech J, Schett G: Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis. Arthritis Res Ther. 2018;20(1):
Bayat S, Baraf HSB, Rech J: Update on imaging in gout: contrasting and comparing the role of dual-energy computed tomography to traditional diagnostic and monitoring techniques Clin Exp Rheumatol. 2018;36 S114(5): S53-S60
Schett G, Bainbridge C, Berkowitz M, Davy K, Fernandes S, Griep E, Harrison S, Layton M, Nowak NA, Patel J, Rech J, Watts S, Tak PP: A Phase IIa Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis Arthritis Rheumatol. 2018;70():
Kampylafka E, d'Oliveira I, Linz C, Lerchen V, Stemmler F, Simon D, Englbrecht M, Sticherling M, Rech J, Kleyer A, Schett G, Hueber AJ: Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study. Arthritis Res Ther. 2018;20(1):
Simon D, Kleyer A, Englbrecht M, Stemmler F, Simon C, Berlin A, Kocijan R, Haschka J, Hirschmann S, Atreya R, Neurath MF, Sticherling M, Rech J, Hueber AJ, Engelke K, Schett G: A comparative analysis of articular bone in large cohort of patients with chronic inflammatory diseases of the joints, the gut and the skin. Bone. 2018;116(): 87-93
Erhard J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber AJ, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz H, Nuesslein H, Alten R, Henes J, Krueger K, Schett G, Rech J: LOOSING DAS28-ESR, BUT STAYING IN BOOLEAN REMISSION-IS IT POSSIBLE? DATA FROM THE PROSPECTIVE, RANDOMISED RETRO TRIAL ON RHEUMATOID ARTHRITIS PATIENTS IN STABLE REMISSION Ann Rheum Dis. 2018;77(): 1307-1308
Stemmler F, Simon D, Liphardt AM, Englbrecht M, Rech J, Hueber A, Engelke K, Schett G, Kleyer A: BIOMECHANICAL PROPERTIES OF RADIAL BONE ARE DIFFERENT BETWEEN AUTO-ANTIBODY POSITIVE AND NEGATIVE RHEUMATOID ARTHRITIS Ann Rheum Dis. 2018;77(): 804-804
Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa A, Combe B, Rech J, Martin R, Ligozio G, Abrams K, Pricop L: Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients Arthritis Rheumatol. 2018;70():
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S: Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial Arthritis Rheumatol. 2018;70():
Simon D, Kleyer A, Faustini F, Englbrecht M, Haschka J, Berlin A, Kraus S, Hueber AJ, Kocijan R, Sticherling M, Rech J, Schett G: Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis - effects of age and disease duration. Arthritis Res Ther. 2018;20(1):
Renner N, Kleyer A, Kroenke G, Simon D, Rech J, Schett G, Welsch G, Pachowsky ML: CARTILAGE DAMAGE QUANTITATIVELY ASSESSED BY MRI USING T2 MAPPING IN CCP-POSITIVE RA PATIENTS Ann Rheum Dis. 2018;77(): 1181-1181
Stemmler F, Simon D, Liphardt AM, Englbrecht M, Rech J, Hueber AJ, Engelke K, Schett G, Kleyer A: Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures. Ann Rheum Dis. 2018;77(7): 973-980
Soare A, Weber S, Maul L, Rauber S, Gheorghiu AM, Luber M, Houssni I, Kleyer A, von Pickardt G, Gado M, Simon D, Rech J, Schett G, Distler JHW, Ramming A: Cutting Edge: Homeostasis of Innate Lymphoid Cells Is Imbalanced in Psoriatic Arthritis. J Immunol. 2018;200(4): 1249-1254
Kamoylafka E, Oliveira ID, Linz C, Lerchen V, Englbrecht M, Simon D, Sticherling M, Rech J, Kleyer A, Schett G, Hueber AJ: DISEASE INTERCEPTION IN PSORIASIS PATIENTS WITH SUBCLINICAL JOINT INFLAMMATION BY INTERLEUKIN 17 INHIBITION WITH SECUKINUMAB - DATA FROM A PROSPECTIVE OPEN LABEL STUDY Ann Rheum Dis. 2018;77(): 199-199
Magorivska I, Döncző B, Dumych T, Karmash A, Boichuk M, Hychka K, Mihalj M, Szabó M, Csánky E, Rech J, Guttman A, Vari SG, Bilyy R: Glycosylation of random IgG distinguishes seropositive and seronegative rheumatoid arthritis. Autoimmunity. 2018;51(3): 111-117
Schoenau V, Schett G, Englbrecht M, Rech J, Roth J: Active Disease and Follow up 18f-FDG-PET/CT in Patients with Giant Cell Arteritis. Which Treatment Is More Likely to Achieve Remission? Arthritis Rheumatol. 2018;70():
Haschka J, Neumann A, Kleyer A, Schuster L, Englbrecht M, Figueiredo CP, Muschitz C, Kocijan R, Resch H, Rech J, Schett G: CORTICAL BONE LOSS IS AN EARLY FEATURE OF AXIAL SPONDYLOARTHRITIS Ann Rheum Dis. 2017;76(): 73-73
Araujo EG, Englbrecht M, Hoepken S, Finzel S, Hueber A, Rech J, Schett G: USTEKINUMAB IS SUPERIOR TO TNF INHIBITOR TREATMENT IN RESOLVING ENTHESITIS IN PSA PATIENTS WITH ACTIVE ENTHESITIS-RESULTS FROM THE ENTHESIAL CLEARANCE IN PSORIATIC ARTHRITIS (ECLIPSA) STUDY Ann Rheum Dis. 2017;76(): 142-142
Schenker H, Hess A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, Hueber AJ, Englbrecht M, Feist E, Voll R, Bannert B, Baerwald C, Roesch J, Doerfler A, da Silva JAP, Damjanov N, Schett G, Rech J: Prediction of Response to Certolizumab-Pegol in Rheumatoid Arthritis By Functional MRI of the Brain - an Interim Analysis of an Ongoing Investigator Initiated Phase III Trial Arthritis Rheumatol. 2017;69():
Haschka J, Hirschmann S, Kleyer A, Englbrecht M, Zimmermann J, Faustini F, Simon D, Figueiredo CP, Cavallaro A, Muschitz C, Kocijan R, Resch H, Atreya R, Rech J, Neurath MF, Schett G: PREVALENCE AND CHARACTERISTICS OF SPONDYLOARTHRITIS ACCORDING TO ASAS CRITERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - RESULTS FROM THE SPICE COHORT Ann Rheum Dis. 2017;76(): 655-655
Schenker H, Hess A, Konerth L, Sergeeva M, Prade J, Kleyer A, Reiser M, Hueber A, Englbrecht M, Feist E, Voll RE, Bannert B, Baerwald C, Roesch J, Doerfler A, Schett G, Rech J: PREDICTION OF RESPONSE TO CERTOLIZUMAB-PEGOL IN RHEUMATOID ARTHRITIS (PRECEPRA) BY FUNCTIONAL MRI OF THE BRAIN - AN INTERIM ANALYSIS OF AN ONGOING INVESTIGATOR INITIATED PHASE III TRIAL Ann Rheum Dis. 2017;76(): 240-240
Kleyer A, Beyer L, Simon C, Stemmler F, Englbrecht M, Beyer C, Rech J, Manger B, Krönke G, Schett G, Hueber AJ: Development of three-dimensional prints of arthritic joints for supporting patients' awareness to structural damage. Arthritis Res Ther. 2017;19(1): 34
Friedberger A, Figueiredo C, Museyko O, Grimm A, dOliveira I, Bauerle T, Rech J, Chaudry O, Uder M, Schett G, Engelke K: QUANTITATIVE ASSESSMENT AND ANALYSIS OF HAND MUSCLE VOLUME Ann Rheum Dis. 2017;76 2(): 247-247
Grossmayer GE, Keppeler H, Boeltz S, Janko C, Rech J, Herrmann M, Lauber K, Munoz LE: Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro. Front Immunol. 2017;8(): 1876
Figueiredo CP, Bang H, Cobra JF, Englbrecht M, Hueber AJ, Haschka J, Manger B, Kleyer A, Reiser M, Finzel S, Tony HP, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Rech J, Schett G: Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann Rheum Dis. 2017;76(2): 399-407
Werner D, Simon D, Englbrecht M, Stemmler F, Simon C, Berlin A, Haschka J, Renner N, Buder T, Engelke K, Hueber AJ, Rech J, Schett G, Kleyer A: Early Changes of the Cortical Micro-Channel System in the Bare Area of the Joints of Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2017;69(8): 1580-1587
Nas K, Cevik R, Yildiz I, Rech J, Schett G: IL-17-22-23 PATHWAYS IN PSORIATIC ARTHRITIS AND PSORIASIS Ann Rheum Dis. 2017;76(): 1324-1324
Tuckwell K, Collinson N, Dimonaco S, Klearman M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Unizony SH, Stone JH, GiACTA Investigators: Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. Semin Arthritis Rheum. 2017;46(5): 657-664
Araujo EG, Englbrecht M, Hoepken S, Finzel S, Hueber AJ, Rech J, Schett G: Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis-Results from the Enthesial Clearance in Psoriatic Arthritis Study Arthritis Rheumatol. 2017;69():
Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figuereido C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G, Rech J: MULTI-BIOMARKER DISEASE ACTIVITY AND AUTOANTIBODY STATUS LEAD TO COST EFFECTIVE TAPERING ALGORITHMS IN RHEUMATOID ARTHRITIS PATIENTS IN SUSTAINED REMISSION Ann Rheum Dis. 2017;76(): 159-159
Wunderlich C, Oliviera I, Figueiredo CP, Rech J, Schett G: Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis. Semin Arthritis Rheum. 2017;46(6): 709-714
Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pascale P, Delicha EM, Pricop L, Mpofu S, Future 1 Study Grp: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL Ann Rheum Dis. 2017;76(): 952-953
Soare A, Weber S, Maul L, Gheorghiu AM, Housni I, Kleyer A, Luber M, Rauber S, Simon D, Rech J, Schett G, Distler J, Ramming A: Innate Lymphoid Cells - New Players in Psoriatic Arthritis Arthritis Rheumatol. 2017;69():
Rech J, Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber A, Manger B, Figuereido C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nuesslein H, Alten R, Henes J, Krueger K, Schett G: ELEVATED MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) PREDICTS RELAPSES IN RA PATIENTS IN SUSTAINED REMISSION TAPERING TUMOUR NECROSIS FACTOR INHIBITOR THERAPY-RESULTS FROM THE RANDOMIZED CONTROLLED RETRO STUDY Ann Rheum Dis. 2017;76(): 516-517
Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, Pascale P, Delicha E, Pricop L, Mpofu S: SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL Intern Med J. 2017;47(): 37-38
Figueiredo C, Simon D, Englbrecht M, Haschka J, Kleyer A, Bayat S, Hueber A, Pereira RM, Rech J, Schett G: QUANTIFICATION AND IMPACT OF SECONDARY OSTEOARTHRITIS USING HR-PQCT IN ANTI-CITRULLINATED PROTEIN ANTIBODY RHEUMATOID ARTHRITIS PATIENTS Osteoporos Int. 2017;28 1(): S110-S111
Renner N, Kleyer A, Simon D, Kroenke G, Rech J, Schett G, Welsch G, Pachowsky ML: Increased Cartilage Damage in Metacarpophalangeal Joints of ACPA Positive Rheumatoid Arthritis (RA) Patients Using T2 Mapping in 3 Tesla Magnetresonance Imaging (MRI) Arthritis Rheumatol. 2017;69():
Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S: Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 J Dtsch Dermatol Ges. 2017;15(): 141-141
Hagen M, Englbrecht M, Haschka J, Reiser M, Kleyer A, Hueber AJ, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Schmitt-Haendle M, Lorenz HM, Nusslein HG, Alten R, Henes JC, Krüger K, Schett G, Rech J: Multi-Biomarker Disease Activity and Autoantibody Status Lead to Cost Effective Tapering Algorithms in Rheumatoid Arthritis Patients in Sustained Remission Arthritis Rheumatol. 2017;69():
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Koetter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schultze-Koops H, Sleight A, Schiffrin E: OPEN-LABEL, MULTICENTER, DOSE-ESCALATING PHASE II CLINICAL TRIAL ON THE SAFETY AND EFFICACY OF TADEKINIG ALPHA IN ADULT ONSET STILL'S DISEASE Ann Rheum Dis. 2017;76(): 709-709
Werner D, Simon D, Englbrecht M, Stemmler F, Berlin A, Haschka J, Renner N, Buder T, Rech J, Engelke K, Hueber AJ, Schett G, Kleyer A: INCREASE OF CORTICAL MICRO-CHANNELS (COMICS) AS A NEW FEATURE OF STRUCTURAL DAMAGE IN PAIENTS WITH RHEUMATOID ARTHRITIS Ann Rheum Dis. 2017;76(): 1011-1012
Schett G, Finzel S, Hagen M, Englbrecht M, Haschka J, Figuereido C, Cobra JF, Rech J: MULTI-BIOMARKER DISEASE ACTIVITY (MBDA) IS ASSOCIATED WITH THE PROGRESSION OF STRUCTURAL BONE DAMAGE IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION Ann Rheum Dis. 2017;76(): 236-236
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N: Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4): 317-328

PD Dr. J. Rech

Medicine 3

Publications: Priv.-Doz. Dr. med. J. Rech